Categories
Blood Cancer

Are we moving away from transplantation for the treatment of myeloma? [Video]

Fredrik Hellem Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, shares some insights into the future treatment landscape of multiple myeloma, drawing focus on the role of transplantation and whether treatment will move away from this approach. Dr Schjesvold highlights the DETERMINATION trial (NCT01208662) and also mentions upcoming trials investigating this, as well as the role of bispecifics in the future of myeloma therapy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

CAR-T in multiple myeloma: cilta-cel & ide-cel [Video]

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, shares his thoughts on how the addition of ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) to the treatment paradigm is adding value to the treatment of patients with multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

CAR-T updates in myeloma [Video]

Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, shares some insights into recent updates in CAR-T therapy for the treatment of multiple myeloma. Prof. Raje first discusses how the approval of ciltacabtagene autoleucel (cilta-cel) has improved options for triple-class refractory and penta-refractory patients, and further explains the promise of idecabtagene vicleucel (ide-cel) and the importance of real-world data. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

CARTITUDE-5: VRd + cilta-cel or Rd in newly diagnosed multiple myeloma [Video]

Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, gives an update on the CARTITUDE-5 study (NCT04923893), which compares the efficacy of bortezomib, lenalidomide and dexamethasone (VRd) induction therapy followed by ciltacabtagene autoleucel (cilta-cel) or lenalidomide and dexamethasone maintenance (Rd) in patients with newly diagnosed multiple myeloma (NDMM) who are transplant-ineligible or that have deferred transplantation until first relapse. The primary endpoint is measurable residual disease (MRD) negativity and secondary endpoints include overall response rate (ORR) and overall survival (OS). The results from this trial are eagerly awaited and could potentially be practice-changing. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

Categories
Blood Cancer

Exciting CAR-T data in multiple myeloma and follicular lymphoma: CARTITUDE-2, ELARA & ZUMA-5 [Video]

Dholaria Bhagirathbhai, MBBS, Vanderbilt University Medical Center, Nashville, TN, shares his thoughts on the most exciting data in CAR-T therapy that will be released at this year’s Tandem Meetings, including results from the CARTITUDE-2 (NCT04133636), ELARA (NCT03568461), and ZUMA-5 (NCT03105336) studies. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

Categories
Blood Cancer

The recent FDA approval of cilta-cel and its impact on myeloma patients in the UK [Video]

In this video, Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the recent FDA approval of ciltacabtagene autoleucel (cilta-cel) for the treatment of multiple myeloma, and the beneficial impact that this will have for patients in the UK. Dr Ramasamy briefly discusses some results from the CARTITUDE-1 (NCT03548207) trial and the excitement around the possibility of cilta-cel being the first CAR-T therapy available for myeloma patients in the UK. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.

Categories
Blood Cancer

The impact of the approval of cilta-cel in multiple myeloma [Video]

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, talks on chimeric antigen receptor T-cell (CAR-T) therapies in multiple myeloma, commenting on the recent approval of ciltacabtagene autoleucel (cilta-cel). The first CAR-T product was approved in pediatric and young adult patients with acute lymphoblastic leukemia (ALL), and its use was later expanded to treat a larger number of indications. The first CAR-T product in multiple myeloma, idecabtagene vicleucel, was approved in 2021 based on the results of the KarMMa trial (NCT03361748). More recently, the highly promising results from the CARTITUDE-1 trial (NCT03548207) led to the approval of cilta-cel by the FDA. According to Prof. Mohty, the addition of cilta-cel to the treatment armamentarium in multiple myeloma will undoubtedly improve the outcomes of patients with R/R disease, and he believes that CAR-Ts will start being used in earlier lines of treatment. Several trials are already comparing CAR-T products versus existing standards of care (SOC) in myeloma. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

Categories
Blood Cancer

Advances in CAR-T therapy for R/R multiple myeloma: ide-cel & cilta-cel [Video]

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the efficacy and promise of BCMA-directed chimeric antigen receptor T-cell (CAR-T) therapies including idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory (R/R) multiple myeloma. Ide-cel was approved in March 2021 for patients with R/R multiple myeloma based on the results of the Phase II KarMMA study (NCT03361748) which reported a median progression-free survival (PFS) of 8.8 months and overall survival (OS) of 19.4 months. The field of CAR-T therapies for multiple myeloma is rapidly evolving, notably with cilta-cel, which showed remarkable results in the Phase Ib/II CARTITUDE-1 trial (NCT03548207), with an overall response rate (ORR) of almost 98% and a 2-year PFS of 71%. In addition, the incidence of severe cytokine release syndrome (CRS) and neurotoxicity was low. These trials highlight the potency of BCMA-directed CAR-T therapies for R/R multiple myeloma and several clinical trials are now evaluating these approaches in earlier lines of treatment. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.

Categories
Blood Cancer

The future of CAR-T therapy for multiple myeloma [Video]

Niels van de Donk, MD, PhD, VU University Medical Center, Amsterdam, Netherlands, talks on the development of CAR T-cell therapy for multiple myeloma. Over recent years, substantial evidence has been gathered to support the use of CAR-T therapy in heavily pretreated patients. Most recently, these efforts led to the FDA approval of idecabtagene vicleucel (ide-cel) for people with multiple myeloma that has relapsed after or is refractory to at least four prior treatments. Ciltacabtagene autoleucel (cilta-cel), another BCMA-directed therapy with two BCMA-targeting single-domain antibodies designed to confer avidity, is also under FDA review and is expected to be approved in the coming months. Prof. van de Donk comments on continued investigations driving the field forwards, including the assessment of new constructs, and testing in earlier stages of disease. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Latest news in myeloma: MRD, BiTEs, and CAR T-cells [Video]

Mohamad Mohty, MD, PhD, Saint Antoine Hospital, Paris, France, shares an insightful overview of the top multiple myeloma news from the ASH 2021 annual meeting and its potential impact on future clinical practice. Prof. Mohty highlights measurable residual disease (MRD) as a key recurring theme at the meeting. Data continues to accumulate that supports the achievement of sustained MRD-negativity as the ultimate goal of treatment. For example, the Phase III GMMG-HD7 trial (NCT03617731) of lenalidomide, bortezomib, and dexamethasone (VRd) with or without isatuximab as induction therapy for newly diagnosed myeloma used the rate of MRD negativity as the primary trial endpoint. Additionally, the MASTER trial (NCT03224507) investigated MRD-based response adapted daratumumab, carfilzomib, lenalidomide and dexamethasone (dara-KRd) consolidation therapy in patients with newly diagnosed myeloma. Prof. Mohty also comments on bispecific antibodies and CAR T-cell therapy presentations as meeting highlights, discussing how the use of these agents may continue to develop over time. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Meta-analysis of cilta-cel in patients with R/R multiple myeloma [Video]

Ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy, is currently being investigated in patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 trial (NCT03548207). Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, provides an overview of findings from a meta-analysis of cilta-cel verus the standard of care. Data from various real world registries and clinical trials such as POLLUX (NCT02076009) and CASTOR (NCT02136134), were analyzed and patients receiving cilta-cel had superior progression-free survival and overall survival. Despite cilta-cel causing more adverse events, patients overall reported a better quality of life. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

CAR-T therapy in multiple myeloma: research blind spots [Video]

CAR T-cell therapy has been shown to elicit high-quality responses in patients with multiple myeloma. Positive data from the pivotal Phase II KarMMa trial led to the approval of idecabtagene vicleucel, a BCMA-directed CAR T-cell therapy, in patients with heavily pretreated relapsed/refractory myeloma, and ongoing trials are investigating the utility of CAR-T versus standard of care regimens in earlier lines of treatment. Andrew Cowan, MD, University of Washington, Seattle, WA, discusses the blind spots in myeloma CAR-T research, highlighting key topics such as treatment sequencing, combination studies, and retreatment with BCMA-targeted therapies. This interview took place at during 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.